There are approximately 150 identified cannabinoids in the cannabis plant. These cannabinoids are broken into categories of ‘Minor’ or ‘Major’. Major cannabinoids, like THC and CBD are widely know and have been studied for some time. Conversely, minor cannabinoids are relatively new, just being studied and are present in plants in low levels, usually less than 1%.

CBG is considered a minor cannabinoid. Because it is a precursor from which all other cannabinoids are synthesized, CBG is often referred to as the “mother” or “stem cell” of cannabinoids. CBG is studied for its many properties, including its ability to help calm inflammation and help kill bacteria. CBG is a non-psychoactive cannabinoid.

Lygos utilizes the tools of biology and chemistry to lead the way in creating the next generation of technologies that will drive the future of the cannabinoid market. Their patented, yeast-based platform enables efficient production of a wide range of natural cannabinoid compounds that are not easily accessible through agricultural means. cannabinoids are derived from specialized yeast in a pure and eco-conscious method. These are the same cannabinoid molecules produced by the cannabis plant. High skincare expertly formulates result-oriented products utilizing to target blemish-prone skin in our High & Bye Collection.

Our bodies contain an endocannabinoid system (ECS) which has receptors CB1 and CB2. In the skin the purpose of this system is to help maintain healthy skin function. CBG interacts with the CB1 and CB2 receptors. Once CBG enters the epidermis (skin), it penetrates to the basal and subcutaneous layers where it helps calm inflammation, reduces blemishes, purifies pores, balances sebum (oil) production and assists with cellular turnover.